HK inno.N to introduce biosimilars for bone disease treatment from Spain

South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to introduce biosimilars of bone loss treatment Prolia and Xgeva.

Under the terms of the agreement, HK inno.N plans to apply for permits by acquiring domestic licenses and copyrights for mAbxience's two biosimilars.

Denosumab, the major active ingredient of Prolia and Xgeva, is effective in preventing osteoporosis and cancer-related skeletal complications. The patent for both drugs is set to expire in 2025.

HK inno.N said that it would secure a new growth engine by quickly seeking domestic approval for the biosimilars after the patent expires.

"We will provide new treatment options to patients through the introduction of biosimilars," said Kwak Dal-won, CEO of HK inno.N.

mAbxience is a biopharmaceutical developer in Spain and is currently conducting clinical trials for denosumab biosimilars.

Write to Jae-Young Han at jyhan@hankyung.com